The short answer: yes, and the delay is substantial

For most well-selected patients, high tibial osteotomy (HTO) does delay total knee replacement — and the delay is measured in years, not months.

The clearest headline figure comes from Primeau et al. (2021), a landmark study cited over 60 times: 79% of knees had not required replacement ten years after medial opening-wedge HTO, with 95% still replacement-free at five years. Pooled data from broader populations align closely — cumulative conversion to knee replacement runs at roughly 6.7% at five years, rising to somewhere between 21% and 36% at ten years. In other words, a clear majority of appropriately selected patients cross a decade with their native knee intact. Across the wider literature, the average estimated delay before eventual replacement is 10–15 years.

It is worth setting one expectation honestly from the outset: HTO is a delay strategy, not a permanent alternative to replacement. For many patients the surgery buys a decade or more of active life before arthroplasty becomes necessary — and the evidence for that delay is genuinely robust. The remainder of this article explains how it works, who it suits, and what the long-term picture looks like.

Why HTO works: the mechanical logic

Picture a car tyre wearing down on one edge: the tread is not defective, the alignment is. Correct the wheel geometry and the tyre wears evenly again. HTO works on the same principle.

In a knee with varus — or bow-legged — deformity, the body's weight-bearing axis runs too far toward the inside of the joint. Nearly all the load passes through the medial compartment, which is typically the side where cartilage has already thinned. That concentrated pressure accelerates further damage in a self-reinforcing cycle.

HTO breaks that cycle by making a precisely calculated cut near the top of the tibia (the shin bone) and opening or closing a small wedge to tilt the bone. This shifts the mechanical axis — the line of force running from hip to ankle — toward the outer (lateral) compartment, which is usually in much better condition. The result is that the damaged medial cartilage is partially offloaded during everyday movement.

Nothing is removed or repaired inside the joint itself. The cartilage remains exactly as it was; what changes is the environment it must survive in. By reducing the load through the damaged medial side, the procedure eases pain and slows further cartilage loss — buying time before replacement becomes necessary.

What the evidence shows at 5, 10, and 20 years

Survival figures across three time horizons tell the most complete story — and the honest version includes the ranges, not just the headline.

At five years

Published cohorts report 86–100% TKR-free survival at this point, with most sitting toward the upper end of that band. The spread reflects variation in how strictly patients were selected rather than any fundamental uncertainty about early outcomes: studies with tighter entry criteria consistently report higher early survival.

At ten years

The ten-year band shows wider variation — 64–97.6% across the literature — and this is where patient selection and surgical technique begin to separate outcomes meaningfully. Primeau et al. (2021), the most-cited contemporary study, recorded 79% survival at this mark. Studies at the lower end of the range typically included older patients or those with more advanced cartilage damage at the time of surgery; those at the upper end reflect stricter selection. Neither extreme is an outlier — the variation is genuine, not a statistical artefact.

At twenty years

Constantin et al. (2024), published in the American Journal of Sports Medicine, provide the most robust long-term data available. Overall survivorship at 20 years was 44%, having been 100% at five years before progressive attrition through the second decade. Framed another way: nearly half of patients in that cohort avoided replacement for two full decades. The three factors most strongly associated with reaching 20 years without TKR were age under 55, BMI under 30, and a WOMAC pain score above 45 at baseline — a finding that reinforces the importance of careful patient selection discussed in the next section.

One contextual point on all three time horizons: the evidence rests largely on cohort studies and registries rather than randomised trials directly comparing HTO against non-operative management or early total knee replacement. The affirmative finding is consistent across the literature, but it has not been confirmed in matched head-to-head trial conditions.

Who is most likely to benefit: patient selection

Three factors most consistently predict who will carry an HTO through to 20 years without needing a replacement: being younger than 55 at the time of surgery, having a BMI below 30, and reporting a WOMAC pain score above 45 at baseline — that is, significant but not end-stage pain at the outset. Constantin et al. (2024) identified all three as significant independent predictors of long-term survivorship. Neither age above 55 nor a BMI modestly above 30 automatically rules a patient out, but clinicians use these thresholds to frame realistic expectations: each factor nudges the expected benefit window shorter.

The ideal candidate beyond those three markers is an active person with isolated medial compartment osteoarthritis, a varus (bow-legged) alignment, a knee that still moves well through its range, and a treatment history that already includes physiotherapy, unloader bracing, and injection-based support. HTO sits clearly after those conservative measures and clearly before joint replacement in the joint-preservation pathway — it is not an early first resort, and it is not appropriate once advanced diffuse arthritis has set in across multiple compartments.

The strongest single predictor of earlier conversion to TKR is the degree of cartilage damage visible on imaging at the time of osteotomy (Primeau et al., 2021). Higher BMI, older age, female sex, and severe pre-operative pain all carry additional risk of a shorter delay window. Severe medial cartilage loss is a relative contraindication for this reason.

One quality-of-care standard worth understanding: surgeons typically perform an arthroscopic inspection of the lateral compartment immediately before making the tibial cut. Because HTO shifts load to that side, confirming the lateral cartilage is in adequate condition to tolerate increased stress is a routine step — a check, not a cause for alarm, and a signal that careful pre-operative assessment is built into the procedure rather than left to chance.

HTO combined with cartilage repair

Correcting alignment addresses the mechanical cause of damage, but the cartilage surface itself remains unchanged. For this reason, HTO is increasingly performed alongside cartilage repair — in a single operation or in staged procedures — so that both the load-distribution problem and the biological defect are treated together.

The cartilage-side partners vary by lesion size and severity. Autologous chondrocyte implantation (ACI) transplants cultured cells harvested from the patient's own knee; microfracture stimulates the marrow beneath the lesion to generate repair tissue; osteochondral transplantation replaces a discrete plug of damaged bone and cartilage with healthy graft from a lower-stress region of the same joint. The right pairing depends on the individual defect, confirmed during pre-operative workup and sometimes verified arthroscopically on the day of surgery. Combining procedures does add surgical complexity and extends recovery — a trade-off that should be discussed explicitly during planning.

For the opposite alignment problem: DFO

Not every patient with unicompartmental knee disease is bow-legged. Where the knee angles inward — the knock-kneed alignment clinicians call valgus — wear falls on the lateral compartment rather than the medial side, and HTO is not the appropriate tool. Distal femoral osteotomy (DFO) performs the equivalent correction from the femur, redirecting load away from the damaged lateral compartment. Published survivorship figures are comparable to those for HTO: 70–90% at 10–15 years. In a 2023 prospective cohort, Ismailidis et al. reported only 7% of DFO patients had required arthroplasty at approximately five years, with 71% satisfied at follow-up.

Where pre-operative planning includes objective biomechanical data — for instance, via MAI Motion® gait analysis — surgeons can quantify load distribution at baseline and use the same measurements to track how well alignment correction has been achieved during recovery.

Setting honest expectations before deciding

The evidence settles a practical question patients rarely ask but should: what happens if HTO eventually stops working? The answer is that conversion to total knee replacement remains entirely feasible after a prior osteotomy — the procedure does not close that door, and most surgeons report no meaningful additional technical difficulty when TKR does eventually become necessary.

For most well-selected patients, that door stays closed for a long time. Constantin et al. (2024, American Journal of Sports Medicine) recorded 100% survivorship at five years before progressive attrition brought the figure to 44% at 20 — meaning the majority will eventually reach the point of replacement, but typically a decade or more later than they would have without the osteotomy. Where a patient sits in the selection criteria shapes how to read that figure honestly. Someone aged 48 with a BMI of 27 falls squarely within the profile associated with the strongest long-term survival. Someone aged 54 with a BMI of 33 may still benefit meaningfully, but the expected window is realistically shorter. The decision is less a binary choice between HTO and replacement and more a question of timing and fit.

One genuine gap in the evidence deserves a mention: how quality of life compares at 15–20 years between patients who converted to TKR early and those who did not is inconsistently reported across cohorts — worth raising in consultation rather than assuming survival-to-replacement data capture the whole picture.

For patients across Lincolnshire and the wider non-London catchment ready to explore these options, MSK Doctors offers consultant-led assessment at Sleaford and Grantham without a GP referral — book directly at mskdoctors.com.